MedTrace Logo

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02420262 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 506

Last updated 2018-03-29

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

insulin degludec/liraglutide

Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

DRUG

insulin glargine

Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

DRUG

insulin aspart

Injected s.c./subcutaneously (under the skin) before each main meal.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-26
Primary Completion
2016-10-05
Completion
2016-10-05

Countries

  • United States
  • Argentina
  • Czechia
  • France
  • Greece
  • Hungary
  • Israel
  • Mexico
  • Russia
  • Slovakia
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02420262 on ClinicalTrials.gov